Bio-Path Holdings, Inc. (NASDAQ:BPTH) fell 7.3% during trading on Monday . The stock traded as low as $0.36 and last traded at $0.38. 545,524 shares changed hands during mid-day trading, a decline of 9% from the average session volume of 600,152 shares. The stock had previously closed at $0.41.

Several brokerages have issued reports on BPTH. HC Wainwright reaffirmed a “buy” rating on shares of Bio-Path Holdings in a research note on Thursday, July 20th. Zacks Investment Research cut shares of Bio-Path Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, ValuEngine cut shares of Bio-Path Holdings from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.

The stock has a 50 day moving average of $0.31 and a 200 day moving average of $0.50. The firm’s market cap is $38.02 million.

Bio-Path Holdings (NASDAQ:BPTH) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). Equities analysts forecast that Bio-Path Holdings, Inc. will post ($0.08) earnings per share for the current year.

Hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC purchased a new position in shares of Bio-Path Holdings in the first quarter valued at $105,000. Bank of New York Mellon Corp increased its position in shares of Bio-Path Holdings by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock valued at $257,000 after buying an additional 5,172 shares in the last quarter. HighTower Advisors LLC increased its position in shares of Bio-Path Holdings by 0.3% in the second quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock valued at $492,000 after buying an additional 4,000 shares in the last quarter. Sabby Management LLC increased its position in shares of Bio-Path Holdings by 3.5% in the first quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock valued at $569,000 after buying an additional 23,352 shares in the last quarter. Finally, Legal & General Group Plc increased its position in shares of Bio-Path Holdings by 5,474.3% in the second quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock valued at $681,000 after buying an additional 1,741,978 shares in the last quarter. Institutional investors and hedge funds own 15.16% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/18/bio-path-holdings-inc-bpth-stock-price-down-7-3.html.

About Bio-Path Holdings

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Receive News & Stock Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related stocks with our FREE daily email newsletter.